TRIMETHAPHAN


Synonyms	Trimetaphan Trimethaphan Trimethaphan cation Trimethaphan ion
Status
Molecule Category	Free-form
UNII	6G8X656T45
EPA CompTox	DTXSID8043787


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	CHQOEHPMXSHGCL-UHFFFAOYSA-N
Smiles	O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1
InChI	InChI=1S/C22H25N2OS/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/q+1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C22H25N2OS+
Molecular Weight	365.52
AlogP	3.66
Hydrogen Bond Acceptor	1.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	4.0
Polar Surface Area	23.55
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	26.0

Assay Description	Organism	Bioactivity
Displacement of [3H]alpha-BGT from nAChR in Torpedo nobiliana electric organs membranes at 300 uM by scintillation counting method	Torpedo nobiliana	5.7 %
Displacement of [3H]PCP from nAChR in Torpedo nobiliana electric organs membranes at 1000 uM by scintillation counting method	Torpedo nobiliana	59.5 %
Displacement of [3H]PCP from nAChR in Torpedo nobiliana electric organs membranes at 300 uM by scintillation counting method	Torpedo nobiliana	5.93 %

Cross References

Resources	Reference
ChEBI	9728
ChEMBL	CHEMBL1201329
DrugBank	DB01116
DrugCentral	2752
FDA SRS	6G8X656T45
Human Metabolome Database	HMDB0015248
KEGG	C07174
PharmGKB	PA451784
PubChem	23576

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).